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Abstract 
A 60-year-old woman, who had been diagnosed with and treated for Vogt-Koyanagi-
Harada (VKH) disease 17 years before, was receiving pegylated interferon-α and ribavirin 
therapy for chronic hepatitis C virus. Three weeks after the start of therapy, she 
complained of visual blurring, eye pain, and an increased hearing loss. Based on a slit 
lamp and fundus examination, she was diagnosed with a relapse of VKH disease. After 
discontinuation of the pegylated interferon-α  and ribavirin therapy and administration 
of corticosteroid therapy, her visual acuity returned to 1.0 in both eyes without ocular 
inflammation, and remained stable thereafter. When interferon therapy is administered 
to hepatitis C virus patients, those who also have a history of VKH disease must be 
closely monitored for ophthalmologic complications. 
 
Introduction 
Starting in 2000, pegylated interferon-α (PEG-IFN) has been the treatment of choice 
for chronic hepatitis C virus (HCV) infections. Typical ocular adverse effects related to 
this treatment include retinopathy. Visual loss is usually absent or limited, and reversible 
after cessation of therapy. However, severe ocular complications have been reported in a 
few cases. Here, we report for the first time a patient who experienced a relapse of Vogt-
Koyanagi-Harada (VKH) disease during treatment with PEG-IFN and ribavirin therapy 
for HCV infection.  
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A 60-year-old woman was referred to our department for fundus examination on June 25, 2008, and 
was scheduled to begin PEG-IFN and ribavirin therapy for chronic HCV infection. She had been 
diagnosed with VKH disease in 1991 and had been treated for 15 months with both injection and oral 
steroid therapies (fig. 1a, b). After the initial treatment, no further symptoms or evidence of the disease 
were observed over the next 17 years. At the time of the examination, she had no symptoms, and her 
visual acuity was 1.2 in her right eye and 1.0 in her left eye. The fundus of both eyes showed a sunset 
appearance, but slit lamp and fundus examinations showed no active inflammation. Based on our 
findings, treatment with PEG-IFN and ribavirin was started. 
At 3 weeks after the start of the therapeutic intervention, the patient complained of visual blurring, 
eye pain, and an increased hearing loss. Her visual acuity was reduced to 0.2 in her right eye and 
remained at 1.0 in her left. A slit lamp examination disclosed bilateral granulomatous uveitis. A fundus 
examination revealed bilateral serous retinal detachment without retinal vasculitis (fig. 2a, b). 
Fluorescein angiography showed multiple leakage of fluorescein dye from the choroid into the 
subretinal space (fig. 2c, d). Auditory acuity was mildly diminished in both ears. As we diagnosed a 
relapse of the patient’s VKH disease, PEG-IFN and ribavirin therapy was discontinued. We began 
administration of intravenous pulses of methylprednisolone (1,000 mg/day for 3 days), followed by 
daily oral corticosteroids, which were then tapered off over time. Two months after the symptoms first 
appeared, her visual acuity returned to 1.0 in both eyes without ocular inflammation and remained 
stable thereafter for more than 15 months. 
Discussion 
Over the last decade, PEG-IFN and ribavirin therapy has become the standard 
treatment for HCV. IFN-α belongs to the type 1 interferon family, which is involved in 
the host’s natural defense against viruses, bacteria, and neoplasia. IFN-α-treated rats with 
experimental autoimmune uveitis have been shown to exhibit only minimal disease [1]. 
Recent publications have emphasized the effects of IFN-α on refractory uveitis, including 
VKH disease [2]. Although the mechanisms of its efficacy are believed to be 
multifactorial, they have not yet been well elucidated. 
In contrast, several autoimmune disorders, such as sarcoidosis, Mooren’s ulcer, 
Graeve’s disease, systemic lupus erythematosus, type I diabetes or rheumatoid arthritis, 
have been observed during IFN-α and ribavirin therapy. These cases have been attributed 
to immunomodulatory actions related to the therapy [3, 4]. There have been some reports 
stating that VKH disease occurs after IFN therapy for HCV. In these reports, the disease 
was indicated to have emerged 3 months to 2 years after the start of IFN therapy [5–7]. In 
the current case, however, we identified the relapse of VKH disease at only 3 weeks after 
starting IFN therapy, even though the disease had been dormant for 17 years. 
The immunological activities of IFN, including enhanced lymphocyte cytotoxity, 
increased expression of major histocompatibility class I antigens, production of 
proinflammatory cytokines, and differentiation of antigen-presenting cells, may 
predispose susceptible individuals to the development of an autoimmune disorder [3–5]. 
Moreover, IFN-α can cause an immune response shift to T-helper-1-type predominance 
and alter the expression of histocompatibility class I and II antigens, possibly leading to 
the development of VKH disease [5, 8]. In addition, administration of IFN-α may lead to 
the development of VKH disease via an increase in the production of endogenous IFN-γ, 
and it has been reported that serum endogenous IFN-γ titers are significantly elevated in 
VKH disease patients [9, 10]. These possible mechanisms may explain how IFN  
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exacerbates preexisting autoimmune conditions and leads quickly to the relapse of VKH 
disease, as shown in this case. 
In conclusion, when IFN therapy is administered to HCV patients, especially those 
who have a history of VKH disease must be closely monitored for ophthalmologic 







Fig. 1. Fluorescein angiographic features of the patient at the initial onset of VKH disease in April 1991. 
Fluorescein angiography shows multiple locations of pinpoint subretinal leakage and serous retinal 
detachment. a Right eye. b Left eye. 
 
  
Case Rep Ophthalmol 2011;2:5–9 
DOI: 10.1159/000323472 
Published online: 
January 7, 2011 







Fig. 2. Fundus photographs of the patient at the second onset of VKH disease in June 2008 after the 
start of PEG-IFN and ribavirin therapy. Both eyes show a sunset appearance with serous detachment (a, 
b). Fluorescein angiography shows multiple locations of pinpoint subretinal leakage corresponding to 
serous retinal detachment (c, d). a, c Right eye. b, d Left eye. 
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